16.12CHF-4.39%Mkt Cap: —P/E: —1d ago
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Euro…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value280.95M $
Revenue (TTM)88.09M $
Gross Profit17.32M $
Net Income (TTM)-56.19M $
Revenue/Share6.769 USD
Last Price16.12 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees93
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINCH0027148649
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-7.57
EV/Revenue3.19
P/S—
P/B-18.71
EPS (TTM)-1.63
EPS (Forward)—
52W Range
15.6234% of range17.10
52W High17.10 CHF
52W Low15.62 CHF
Profitability
Gross Margin19.66%
Oper. Margin-4.08%
EBITDA Margin-42.15%
Profit Margin-63.79%
ROE-620.02%
ROA-15.64%
Growth
Revenue Growth112.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.68M $
CapEx (TTM)—
FCF Margin-46.17%
FCF Yield—
Net Debt30.25M $
Net Debt/EBITDA-0.81
Balance Sheet
Debt/Equity—
Current Ratio1.29
Quick Ratio0.78
Book Value/Sh-0.8820 CHF
Cash/Share1.675 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.1:1
Split DateJul 3, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.6.44M
Float11.27M
Insiders14.57%
Institutions11.10%
Technical
SMA 509.905 (+62.7%)
SMA 2008.978 (+79.5%)
Beta-0.28
S&P 52W Chg20.80%
Avg Vol (30d)2.73K
Avg Vol (10d)1.43K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—